We are international
Donate
• health professionals TEXT SIZE   
webcasts

FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Study met primary efficacy endpoint of non-inferiority between subcutaneous and intravenous administration.
Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy.
01.23.12

The approval is based on results from a randomized, phase 3 trial conducted with 222 bortezomib-naïve relapsed patients in 53 centers in 10 countries across Asia, Europe, and South America. Patients receiving VELCADE subcutaneously achieved an overall response rate similar to that of those receiving VELCADE intravenously. The important difference is that the rate of peripheral neuropathy was substantially lower in the subcutaneous arm of the trial.

What that means for those of us in the myeloma community is that physicians treating patients including those with poor vein access or who have peripheral neuropathy and those at high risk of developing it now have another weapon in their armamentarium against myeloma.

Read the press release from Millennium: The Takeda Oncology Company about the approval.

 related articles
ASH 2011: Dr. Moreau - Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics
Dr. Moreau - A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
Dr. Noopur Raje Discusses Her Research Interests in MM, Including Subcutaneous VELCADE


You might also be interested in:

ASH 2011: Dr. Moreau - Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics
Philippe Moreau, MD
University Hospital
Nantes, France

Dr. Moreau - A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
Philippe Moreau, MD
University Hospital
Nantes, France

Dr. Noopur Raje Discusses Her Research Interests in MM, Including Subcutaneous VELCADE